How ElevateBio Is Betting On Every Gene Editing Modality At Once

On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. ElevateBio's chief scientific officer Amy Pooler joins In Vivo's David Wild to argue that the answer isn't one technology, but many. In this episode, Pooler walks through ElevateBio's full editing stack: AI-designed large serine recombinases, retrotransposon-based insertion, generative AI-optimized base editors, and an LNP delivery platform that has now shown re-dosing and therapeutically meaningful editing in non-human primates. She also makes the case for epigenetic editing as a potentially underappreciated modality, one that could compete with small molecules in indications where you want potency and specificity without permanently rewriting the genome. And she explains why ElevateBio, with six consecutive years of revenue growth and a 98% manufacturing batch success rate, sees its end-to-end CDMO model as uniquely positioned to turn those tools into medicines partners can actually bring to the clinic.